Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Average Rating of “Buy” by Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have earned a consensus recommendation of “Buy” from the five research firms that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $10.33.

Several research firms have recently issued reports on CRBU. Bank of America decreased their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Citigroup reduced their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research report on Friday, November 15th.

Hedge Funds Weigh In On Caribou Biosciences

Several hedge funds have recently bought and sold shares of the company. Milestone Asset Management LLC boosted its stake in Caribou Biosciences by 5.6% during the fourth quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock valued at $260,000 after buying an additional 8,662 shares during the period. Thrive Wealth Management LLC bought a new stake in shares of Caribou Biosciences during the 4th quarter valued at about $51,000. Green Alpha Advisors LLC grew its holdings in shares of Caribou Biosciences by 75.4% during the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares in the last quarter. Barclays PLC increased its position in shares of Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Up 9.2 %

CRBU opened at $1.43 on Friday. Caribou Biosciences has a 1-year low of $1.30 and a 1-year high of $8.33. The company has a market cap of $129.49 million, a P/E ratio of -0.87 and a beta of 2.34. The company has a fifty day moving average price of $1.77 and a two-hundred day moving average price of $1.98.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. On average, research analysts forecast that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.